Natera, Inc. (NASDAQ:NTRA) CEO Sells $889,769.79 in Stock

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CEO Steven Leonard Chapman sold 5,343 shares of the company's stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $166.53, for a total transaction of $889,769.79. Following the sale, the chief executive officer owned 173,728 shares in the company, valued at $28,930,923.84. The trade was a 2.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, June 2nd, Steven Leonard Chapman sold 6,111 shares of Natera stock. The shares were sold at an average price of $157.10, for a total value of $960,038.10.
• On Thursday, May 1st, Steven Leonard Chapman sold 6,980 shares of Natera stock. The stock was sold at an average price of $150.10, for a total value of $1,047,698.00.
• On Monday, April 28th, Steven Leonard Chapman sold 6,203 shares of Natera stock. The shares were sold at an average price of $152.18, for a total value of $943,972.54.
• On Monday, April 21st, Steven Leonard Chapman sold 1,664 shares of Natera stock. The stock was sold at an average price of $145.55, for a total transaction of $242,195.20.

Natera Trading Down 0.0%

Shares of NTRA traded down $0.07 during mid-day trading on Friday, reaching $161.50. The company's stock had a trading volume of 468,868 shares, compared to its average volume of 1,422,668. Natera, Inc. has a 52 week low of $92.14 and a 52 week high of $183.00. The stock has a market cap of $22.05 billion, a PE ratio of -109.86 and a beta of 1.73. The company's fifty day moving average price is $160.18 and its two-hundred day moving average price is $158.47.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.09. Natera had a negative net margin of 10.36% and a negative return on equity of 18.29%. The business had revenue of $501.83 million during the quarter, compared to the consensus estimate of $446.68 million. During the same period in the previous year, the firm posted ($0.56) earnings per share. The firm's revenue for the quarter was up 36.5% on a year-over-year basis. Research analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on NTRA. Piper Sandler upped their target price on shares of Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Thursday, May 15th. Royal Bank Of Canada initiated coverage on shares of Natera in a report on Thursday, March 13th. They issued an "outperform" rating and a $251.00 price target on the stock. Wall Street Zen lowered Natera from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th. Barclays boosted their target price on Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a research report on Friday, May 9th. Finally, UBS Group raised their price target on Natera from $211.00 to $218.00 and gave the company a "buy" rating in a report on Friday, May 9th. One investment analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $184.63.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. AG2R LA Mondiale Gestion D Actifs bought a new stake in Natera in the 1st quarter worth $1,136,000. Swedbank AB grew its stake in shares of Natera by 48.8% in the first quarter. Swedbank AB now owns 45,135 shares of the medical research company's stock worth $6,383,000 after purchasing an additional 14,809 shares during the last quarter. Strs Ohio purchased a new position in Natera during the 1st quarter valued at about $8,992,000. Geneos Wealth Management Inc. raised its position in Natera by 142.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 1,098 shares of the medical research company's stock valued at $155,000 after purchasing an additional 646 shares during the last quarter. Finally, IFM Investors Pty Ltd purchased a new stake in Natera in the 1st quarter worth approximately $3,498,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.